Cardiovascular Journal of Africa: Vol 26 No 2 (March/April 2015)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 26, No 2, March/April 2015

AFRICA

28–39.

Grundy SM, Brewer B, Cleeman JI, Smith SC Jr, Lenfant C. Definition

of metabolic syndrome: Report of the National Heart, Lung, and Blood

Institute/American Heart Association Conference on Scientific Issues

Related to Definition.

Circulation

2004;

109

: 433–438.

Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabe-

tes associated with the metabolic syndrome: a summary of evidence.

Diabetes care

2005;

: 1769–1778.

Reaven GM. Banting lecture 1998. Role of insulin resistance in human

disease.

Diabetes

1988;

: 1595–1607.

Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the meta-

bolic syndrome, and risk of incident cardiovascular events: an 8-year

follow-up of 14,719 initially healthy American women.

Circulation

2003;

107

: 391–397.

10. ChapmanMJ. Metabolic syndrome and type 2 diabetes: lipid and physio-

logical consequences.

Diabetes Vasc Dis Res

2007;

(suppl): S5–S8.

11. Wang CM, Kaltenboeck B. Exacerbation of chronic inflammatory

diseases by infectious agents: Fact or fiction?

World J Diabetes

2010;

: 27–35.

12. Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan

et al

. The effect of

Helicobacter pylori

on insulin resistance.

Dig Dis

Sci

2005;

: 2090–2093.

13. Ekesbo R, Nilsson PM, Lindholm LH, Persson K, Wadström T.

Combined seropositivity for

H. pylori

and

C. pneumoniae

is associated

with age, obesity and social factors.

J Cardiovasc Risk

2000;

: 191–195.

14. Bonfanti P, Ricci E, de Socio G,

et al

. Metabolic syndrome: a real threat

for HIV-positive patients? Results from the SIMONE study.

J Acquir

Immune Defic Syndr

2006;

: 128–131.

15. Bonfanti P, Giannattasio C, Ricci E,

et al

. HIV and metabolic syndrome:

a comparison with the general population

. J Acquir Immune Defic Syndr

2007;

: 426–431.

16. Carr A, Samaras K, Burton S,

et al.

A syndrome of peripheral lipo-

dystrophy, hyperlipidemia and insulin resistance due to HIV protease

inhibitors.

AIDS

A998;

: F51–58.

17. Huypmann AR, Orenstein JM. Opportunistic disorders of the gastroin-

testinal tract in the age of highly active antiretroviral therapy.

Hul Pathol

2010;

: 1777–1787.

18. Coats AJS, Shewan LG. Statement on authorship and publishing ethics

in the

International Journal of Cardiology. Int J Cardiol

2011;

153

239–240.

19. World Health Organization: acquired immune deficiency syndrome

(AIDS): interim proposal for a WHO staging system for HIV-A infec-

tion and disease.

Wkly Epdemiol Rec

1990;

: 221–228.

20. Centers for disease control and prevention: 1993 revised classification

system for HIV infection and expanded surveillance case definition for

AIDS among adolescents and adults.

MMWR Recomm Rep

1992;

1–19.

21. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force consen-

sus group. The metabolic syndrome-a nex worldwide definition.

Lancet

2005;

366

: 1059–1062.

22. Longo-Mbenza B, Bieleli E, Muls E, Vangu N, Ditu Mpadamadi S. The

role of early hemodynamic impairment and disease duration on diabetic

cardiomyopathy and hypertension in central Africans with atherosclero-

sis

. J Diabetes Complicat

2002,

: 146–152.

23. Longo-Mbenza B, Kasiam Lasi On’kin JB, Nge Okwe A, Vangu Ngoma

D, Mbungu Fuele S, Milongo Dipa G. Comparison of abdominal

obesity and total obesity in predicting risk of prehypertension status

with reference to economic development in the south-west of Congo.

Circulation

2008;

117

[Abstract 0169].

24. Iacobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G,

Barbaro G. Epicardial adipose tissue is related to carotid intima–media

thickness and visceral adiposity in HIV-infected patients with highly

active antiretroviral therapy-associated metabolic syndrome.

Curr HIV

Res

2007;

: 275–279.

25. Fezeu L, Balkau B, Kengne AP, Sobngwi E, Mbanya JC. Metabolic

syndrome in a sub-Saharan African setting: Central obesity may be the

key determinant.

Atherosclerosis

2007;

193

: 70–76.

26. Currier J. Management of metabolic complications of therapy.

AID

2002;

(Suppl 4): S171–S176.

27. Staszewski S, Gallant J, Posniak A,

et al

. Efficacy and safety of tenofovir

disproxil fumarate (TDF) versus stavudine (d4T) when used in combi-

nation with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected

patients naive to antiretroviral therapy (ART): 48-week interim results.

XIV International AIDS Conference. Barcelona, 2002.

28. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and

management.

AIDS

2003;

(suppl 1): 141–148.

29. Longo-Mbenza B, Seghers KV, Phuati M, Bikangi FN, Mubagwa K.

Heart involvement and HIV infection in African patients: determinants

of survival.

Int J Cardiol

1998;

: 63–73.

30. Bau, MK, Rafie C, Lai S,

et al.

Coronary heart disease (CHD) risk

factors and metabolic syndrome in HIV-positive drug users in Miami.

Am J Infect Dis

2006;

: 173–179.

31. Mochan A, Modi M, Modi G. Stroke in black South African

HIV-positive patients. A prospective analysis.

Stroke

2003;

: 10–15.

32. Samarasinghe YP, Higgs C, Gazzard B, Feher MD. Diabetes in a HIV

population: a hidden epidemic.

Diab Met

2002;

(Suppl 2): 28–115.